Minneota, MNNCT03593759Now EnrollingIRB Ready

Cardiac Sarcoidosis Clinical Trial in Minneota, MN

Access cutting-edge cardiac sarcoidosis treatment through this phase 3 clinical trial at a research site in Minneota. Study-provided care at no cost to qualified participants.

Sponsored by Ottawa Heart Institute Research Corporation

Quick Self-Assessment

See if you qualify for this Minneota location

Preparing your pre-screening questions…

Expert Care in Minneota

Access cardiac sarcoidosis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related cardiac sarcoidosis treatment provided free

Apply for This Minneota Location

Check if you qualify for this cardiac sarcoidosis clinical trial in Minneota, MN

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Minneota

    Convenient for MN residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Minneota site if eligible
  4. 4Begin participation

About This Cardiac Sarcoidosis Study in Minneota

Prospective randomized controlled trial comparing low dose Prednisone(or Prednisolone)/Methotrexate combination to standard dose Prednisone(or Prednisolone) in patients diagnosed with acute active clinically manifest cardiac sarcoidosis and not yet treated. The Investigators hypothesize that low dose Prednisone(or Prednisolone)/Methotrexate combination will be as effective as standard dose Prednisone(or Prednisolone), and result in significantly better quality of life and less toxicity than sta

Sponsor: Ottawa Heart Institute Research Corporation

Who Can Participate

Inclusion Criteria

(i) Cardiac sarcoidosis presenting with one or more of the following clinical findings:
advanced conduction system disease (defined as Mobitz II AV block or third degree AV block)
significant sinus node dysfunction (defined as average HR less than 40bpm when awake and/or sustained atrial arrhythmias)
non- sustained or sustained ventricular arrhythmia
left ventricular dysfunction (LVEF \< 50%)
right ventricular dysfunction (RVEF \< 40%) AND (ii) No alternative explanation for clinical features AND (iii) Nuclear Imaging within six-months of enrollment consisting of FDG-PET scan with FDG uptake suggestive of active CS and myocardial perfusion imaging AND ONE OR BOTH OF FOLLOWING (iv) Positive biopsy for Sarcoid (either EMB or extra-cardiac) (v) CT Chest showing features consistent with pulmonary sarcoidosis and/or mediastinal and/or hilar lymphadenopathy

Exclusion Criteria

Current or recent (within two months) non-topical treatment for sarcoidosis
Current Oral/IV treatment of duration greater than 5 days
Currently taking Methotrexate or Prednisone for another health condition
Intolerance or contra-indication to Methotrexate or Prednisone
Patient does not meet all of the above listed inclusion criteria
Patient is unable or unwilling to provide informed consent
Patient is included in another randomized clinical trial
Patient has a contraindication to PET imaging or is unlikely to tolerate due to severe claustrophobia
Pregnancy (all women of child bearing age and potential will have a negative BHCG test before enrollment)
Breastfeeding
Women of childbearing age who refuse to use a highly effective and medically acceptable form of contraception throughout the study
Patients for whom the investigator believes that the trial is not in the interest of the patient

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Minneota?

Yes, this clinical trial (NCT03593759) has an active research site in Minneota, MN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Cardiac Sarcoidosis Treatment Options in Minneota, MN

If you're searching for cardiac sarcoidosis treatment options in Minneota, MN, this clinical trial (NCT03593759) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Minneota research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced cardiac sarcoidosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all cardiac sarcoidosis clinical trials near you to find additional studies recruiting in your area.

More Sarcoidosis Trials in Minneota, MN

See all sarcoidosis clinical trials recruiting in Minneota — not just this study.

Browse Sarcoidosis Trials in Minneota →

Browse More Trials by Condition

Sarcoidosis TrialsOsteogenesis Imperfecta TrialsAll Conditions →

Ready to Join in Minneota?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Minneota, MN